CTOR
CITIUS ONCOLOGY, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$0.54
−6.40%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -69.3%
- EBIT
- -85.6%
- EPS
- -27.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +1239.2%
- EBITDA
- +180.9%
- EPS
- +141.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -14.2%
- EBIT
- -14.3%
- Net income
- -17.1%
- EPS
- -13.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026